Novel Coronavirus (SARS-CoV-2) Main Protease: Molecular docking of Puerarin as a Potential inhibitor

Oluwafemi Adeleke Ojo (oluwafemiadeleke08@gmail.com)  
Landmark University, Omu-Aran, Nigeria  https://orcid.org/0000-0001-9331-396X

Adebola Busola Ojo  
Ekiti State University, Nigeria

Odunayo Anthonia Taiwo  
Chrisland University, Abeokuta, Nigeria

Olarewaju M Oluba  
Landmark University, Omu-Aran, Nigeria

Research Article

Keywords: Puerarin, molecular docking studies, SARS-CoV-2 main protease, toxicity prediction

Posted Date: June 26th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-37794/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

SARS-CoV-2 a single stranded RNA virus which triggered the global pandemic Coronavirus Disease- 2019 (COVID-19). It has infected about 2,844,712 patients and brought forth mortality rate to about 201,315 among 216 countries as cited by WHO. Drugs including Chloroquine and Hydroxychloroquine derivatives are being administered in most urgent cases; although, with probable side effects to people with metabolic disorders. Thus, unavailability of authorized drugs and treatment for this pandemic demands the research world to discover natural compounds with potency to cure it. This paper assesses the isoflavonoid puerarin from Pueraria lobata as a possible inhibitor of the main protease of SARS-COV-2 (Mpro) via in silico approach, for example molecular docking, Lipinski’s rule of five and toxicity prediction (ADME). Puerarin revealed high binding affinity with the target site of SARS-CoV-2 main protease. This compound slightly meets the criteria of Lipinski’s rule and does not possess properties that could cause adverse effects in humans thus, making puerarin a potential drug candidate to investigate for its usage against COVID-19.

Introduction

Coronaviruses (CoVs), are single-stranded RNA viruses, that can infect animals and humans, resulting in respirational, gastrointestinal, liver, and brain diseases (Weiss and Leibowitz, 2011). Being the biggest recognized RNA viruses, CoVs are additionally grouped into four classes: α-coronavirus, betacoronavirus, γ-coronavirus and δ-coronavirus (Yang and Leibowitz, 2015). Thus far, six human coronaviruses (HCoVs) have been recognized, comprising the α-CoVs HCoVs-NL63 and HCoVs-229E and the β-CoVs HCoVs-OC43, HCoVs-HKU1, severe acute respiratory syndrome-CoV (SARS-CoV) (Drosten et al. 2020), and Middle East respiratory syndrome-CoV (MERS-CoV) (Zaki et al., 2012).

From late December 2019, the symptoms such as high fever, cough, tiredness, phlegm production, difficulty in breathing started to increase as cluster of pneumonia were noticed and recognized as beta-coronavirus in Wuhan, Hubei Province, China (Wang et al., 2020). The beta-coronavirus was primarily and officially termed as 2019- novel coronavirus (2019-nCoV) and coronavirus 2019 (COVID- 19) respectively by WHO while the International Committee of Coronavirus Study Group (CSG) suggested the usage of the term SARS- CoV-2 (Guo et al., 2020). Through the sequential analysis study of the virus, bat was thought as the biological host of the virus. This virus is transmitted between humans by binding to angiotensin converting enzyme-2 receptor (Zhou et al., 2020).

Various kinds of medications have been suggested which are largely antiviral drugs and are currently being used clinically (Gautret et al., 2020; Huang et al., 2020). In the meantime, chloroquine phosphate and hydroxychloroquine sulphate are being administered for the urgent treatment of COVID-19 by the recommendations gotten from in vitro and some clinical studies data although the Food and Drug Administration (FDA) specified that these drugs are not yet accepted due to some recent experiments.
revealing that hydroxychloroquine can result in deleterious and reasonable austere effects in individuals who are already being treated for metabolic disorders. Furthermore, treatment of hydroxychloroquine was perceived to impede inflammatory cytokines (Guastelgname and Vallone et al., 2020).

Due to the side effects hydroxychloroquine have on the viral proteins associated in the life cycle of the virus, a new effective drug candidate with less side effects needs to be established. In silico studies of chemically synthetic drugs for example Darunavir have been reported (Khan et al., 2020). Also, several treatment target sites for handling COVID-19 have been established, SARS-CoV-2 main protease was preferred as a result of the potential in handling CoV-2 patients and stopping the multiplying process of the virus (Jin et al., 2020).

Phytomolecules are rapidly produced, cheap and are right candidate for compositions of drugs of interest. This model of repositioning phytocompounds in drug discovery will accelerate the process. Thus, the exploration for effective natural compounds with promising ability to inhibit the main protease. (Khaerunnisa et al., 2020). Puereria lobata also known as Kudza is a fast developing perennial vine arising from China. The plant is eatable with health sustaining benets of Kudzu arising from its flowers and roots, which comprise numerous phytomolecules such as isoflavones and saponins (Li et al. 2010). Puereria lobata was reported to have anti-viral property against HIV-1 replication by inhibiting the entry of HIV-1 into target cells (Mediouni et al. 2018). The bioactive compound in Puereria lobata is puerarin. Puerarin possesses many pharmacological activities, comprising anti-diabetic, anti-cancer, anti-inflammatory, and anti-viral activities (Wu et al., 2013; Gan and Yin, 2015; Zhu et al., 2015; Ullah et al., 2018). Puerarin has been reported to have antiviral properties against Porcine epidemic diarrhea virus. As a result of these interests, this work engages the molecular docking analysis of puerarin against SARS-CoV-2 main protease.

**Materials And Methods**

**Molecular Interaction of Puerarin with SARS-CoV-2 main protease**

**Target preparation and Docking**

SARS-CoV-2 main protease 3D structure was downloaded from Protein Data Bank (PDB with ID number 6W63). To monitor the interaction modes of puerarin with SARS-CoV-2 main protease, the Maestro Molecular Modeling platform (version 11.5) by Schrödinger, LLC was used. The Protein Preparation Wizard module was used to prepare the structure. The Glide receptor grids constructed based on the co-crystalized ligand-binding sites in the Glide application (Glide, version) of Maestro. The center of each grid was arranged at the centroid of the crystalized ligand-binding site which is set with inner (acceptable space for the ligand center) and outer (search space surrounded all the ligand atoms) box sizes of 10 and 20 Å, respectively by virtual screening workflow (Bagherzadeh et al., 2020). The extra precision (XP) Workflow in Maestro was used to dock puerarin with SARS-CoV-2 main protease. During the molecular docking full flexibility of the protein and puerarin were considered. The maestro software was used to determine protein-ligand interaction.
ADMET predictions

ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) analyses establishes the pharmacokinetics of a drug molecule. Swissadme (http://www.swissadme.ch) and admetSAR (predated.bmdrc.kr) servers were used in this study to predict and describe significant druglikeness such as mutagenicity, toxicological dosage level and pharmacologically relevant properties of the compounds (Elekofehinti et al., 2018).

Results

The 3D structure of the puerarin and lopinavir was modeled and used as a target for docking simulation against SARS-CoV-2 (Figure 1). Puerarin and lopinavir structures (Figure 2) were downloaded from pubmedchem and prepared for the docking (3D) using Maestro Molecular Modeling platform.

The molecular docking scores and binding affinity of puerarin with –OH, puerarin with –O and lopinavir (standard protease inhibitor) with SARS-CoV-2 protease produced negative values for free energy -8.070 and -4.658 Kcal/mol as well as lopinavir with -8.081 Kcal/mol in the grid box, indicating high interaction with the binding pocket (Table 1).

Puerarin with –OH revealed good docking score and higher binding interaction found rooted into the binding cavity of SARS-CoV-2 displaying all the major interaction (Figure 3) compared with lopinavir a protease inhibitor (Figure 5). Also, lopinavir showed a good docking pose with SARS-CoV-2 than puerarin with –O which exhibited the lowest binding energy (Figure 4).

Data presented in Table 2 shows that puerarin slightly meet all the requirements of the rule of five. Puerarin has H-bond donor value of 6.

Data as predicted using admetSAR server revealed the prospective ADME profiles of the puerarin. ADMET properties, as derived from admetSAR server, reveal that puerarin had no significant ADME properties that could cause antagonistic effects in humans (Table 3). It was predicted to have high human intestinal absorption (HIA), not blood brain barrier permeant, inhibits CYP2C19, CYP2C9 and CYP3A4 cytochromes, and plasma protein binding value was found to be 54.383253. Skin and MDCK (Madin Darby canine kidney) permeability values was -4. 6011 and 3.99199 respectively. The result in this study (AMES Test) shows puerarin is not a potential mutagen and non-carcinogen.

Discussion

With the aim of combating the high death rate caused by SARS-CoV-2 virus, numerous compounds are already in trial to give antidote to this terrible disease plague. Numerous scholars have gone on several studies that can be employed to derive various therapeutic substitute in the cure of SARS-CoV-2 virus (Bagherzadeh et al., 2020). Furthermore, hydroxychloroquine is being given to emergency cases, though, it was reported to elevate the hydrogen ion concentration of protease and documented as a possible
SARS-CoV-2 inhibitors (Bagherzadeh et al., 2020; Wang et al., 2020). Although, the use of hydroxychloroquine is not without severe side effects but effective, there is need to provide alternative measures with little or no side effects. Hence, the use of natural plant products such as puerarin are safe, cheap, readily available with no known side effects.

Puerarin, a potent bioactive compounds extracted from *Pueraria lobata* was used in this study due to its overwhelming properties. This compound was analyzed using molecular simulation tools against SARS-CoV-2 main protease virus showing a high binding affinity (-8.070 Kcal/mol) with the active site residues when compared to lopinavir, a protease inhibitor with binding energy value of -8.081 Kcal/mol. Although, some bioactive compounds reported to inhibit SARS-CoV-2 protease was not capable to prove their binding affinity when likened to puerarin. Examples of such compounds include quercetin -8.58 Kcal/mol, demethoxycurcumin -8.17 Kcal/mol and kaempferol -9.41 Kcal/mol, respectively (Khaerunnisa et al., 2020). Thus indicating that puerarin has a better inhibitory property against SARS-CoV-2 protease.

Lipinski’s rule of five is a technique used to assess drug-likeness of a chemical compound to ascertain whether a chemical compound has certain biological activities or pharmacological properties that would make it a possible effective oral drug in humans (Lipinski, 2004). It also aids in illustrating high possibility of failure or success due to drug-likeness of molecules fulfilling the underlying rules such as; molecular mass \(\leq 500\) Dalton, high lipophilicity, which is represented as LogP should be less than 5, hydrogen bond donors not greater than 5, hydrogen bond acceptor not more than 10 and molar refractivity should be between 40-130 (Lipinski, 2004; Oyinloye et al., 2019).

Puerarin revealed exceptional druggability properties which is confirm as a result of its molar refractivity which indicates the its ability to pass through specific biomembranes amid weak or strong interactions. Furthermore, the lipophilicity of puerarin reveals its characteristics for oral absorption. Though, puerarin slightly obey the Lipinski rule of five, it can act as a drug candidate which is laudable of testing in biological systems.

The ADME data, predicted that puerarin had no significant ADME properties that can lead to serious side effects in humans. It is also a non-inhibitor of p-gp inhibition indicating the ability to liberate phosphate group from adenosine triphosphate and concurrent bonding of adenosine diphosphate to glycoprotein. The capability of puerarin to infiltrate blood brain barrier is of remarkable benefit, as it suggests a therapeutic effect against glucose – neurotoxicity. The prediction of human absorption via Caco-2 based penetration assay is routinely performed during drug development. However, puerarin could satisfy as a good drug as it has easy passage through the blood brain barrier, human intestinal absorption and Caco-2 penetration. Puerarin is also not mutagen neither carcinogenic as indicated in the data present.

The safety and toxicity of medicinal plants remains a giant concern to health practitioners particularly modulation of cytochrome P450 enzyme family (CYP) and P-glycoprotein (P-gp) due to the therapeutic consequence they have, as CYPs are the most recognized enzymes involved in biotransformation of drug. (Elekofehinti et al., 2018). The predicted inhibition of CYP2C9, CYP2C19, and CYP3A4 by puerarin, hence proposes its significant role in drug metabolism. Puerarin does not halt the metabolism of numerous
beneficial drugs through the inhibition of CYP2C19, oxidation of steroids, fatty acids and biotransformation of drugs in addition to the synthesis and degradation of hormones via the inhibition of CYP3A4. Taken together, puerarin has good binding affinity with SARS-CoV-2 slightly meeting the Lipinski’s rule of five and has good ADME toxicity profile. The ADMET prediction revealed puerarin as a safe compound which can be given as a drug. Although, the properties are considerable in silico data, additional findings from in vitro, clinical and preclinical investigations addressing SARS-CoV-2 ought to be deliberated on.

**Declarations**

**Conflict of Interest**

There is no conflict of interest expressed by the authors.

**References**

Bagherzadeh K, Daneshvarnejad K, Abbasinazari M, Azizan H. In silicon repositioning for dual inhibitor discovery of SARS-CoV-2 (COVID-19) 3C-Like protease and papain-like peptidase. 2020; Doi:10.20944/preprints202004.0084.v1

Drosten C, Günther S, Preiser W. Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome. N Engl J Med 2020; 348:1967-76.

Elekofehinti OO, Opeyemi I, Ayodeji F, Damilare A, Bulu Y, Rocha JBT, Ejelonu OC, Kamdem JP, Akinlosotu O. Discovery of potential vistatin activators using in silico docking and ADME predictions as therapy for type-2- diabetes. Beni – suef University Journal of Basic and applied Sciences 2018; Doi.org/10.1016/j.bjbas.2018.02.007

Gan M, Yin X. Puerarin induced in mantle cell lymphoma apoptosis and its possible mechanisms involving multi-signaling pathway. Cell Biochem Biophys. 2015;71(1):367–373.

Gautret P, Lagier J, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honoré S, Colson P, Chabrière E, La Scola B, Rolain J, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, 2020; 105949.

Guastalegname M, Vallone A. Could chloroquine/Hydroxychloroquine be harmful in coronavirus disease 2019 (COVID-19) treatment? Clinical Infectious Diseases 2020; https://doi.org/10.1093/cid/ciaa321

Guo Y, Cao Q, Hong Z, Tan Y, Chen S, Jin H, Tan K, Wang D, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Medical Research, 2020; 7(1).
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*, 2020; 395(10223), 497-506.

Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, et al. Structure of Mpro from COVID-19 virus and discovery of its inhibitors. *Nature*. 2020; https://doi.org/10.1038/s41586-020-2223-y

Khaerunnisa S, Kurniawan H, Awaluddin R, Suhartati S, Soetjipto S. Potential inhibitor of COVID-19 main protease (Mpro) from several medicinal plant compounds by molecular docking study. 2020; https://doi.org/10.20944/preprints202003.0226.v1

Khan SA, Zia K, Ashraf S, Uddin R, Ul-Haq Z. Identification of chymotrypsin-like protease inhibitors of SARS-Cov-2 via integrated computational approach. *Journal of Biomolecular Structure and Dynamics*, 2020; 1-10.

Li G, Zhang Q, Wang Y. Chemical constituents from roots of *Pueraria lobata*. Zhongguo Zhong Yao Za Zhi. 2010;35:3156–60.

Lipinski CA. Lead- and drug-like compounds: the rule-of-fiverevolution. Drug Discov Today Technol 2004; 1: 337-41.

Mediouni S, Jablonski JA, Tsuda S, Richard A, Kessing C, Andrade MV, Biswas A, Even Y, Tellinghuisen T, Choe H, Cameron M, Stevenson M, Valente ST. Potent suppression of HIV-1 cell attachment by Kudzu root extract. *Retrovirology*. 2018 15:64.

Oyinloye BE, Adekiya TA, Aruleba T, Ojo OA, Ajiboye BO. *Structure based docking studies of GLUT4 towards exploring selected phytochemicals from Somalia xanthocarpum as a therapeutic target for the treatment of cancer*. *Current Drug Discovery Technologies*, 2019; 16(4): 406-416 doi: 10.2174/1570163815666180801152110.

Ullah MZ, Khan AU, Afridi R, Rasheed H, Khalid S, Naveed M, et al. Attenuation of inflammatory pain by puerarin in animal model of inflammation through inhibition of pro-inflammatory mediators. Int Immunopharmacol. 2018; 61:306-16.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. *JAMA*, 2020; 323(11), 1061.

Weiss SR, Leibowitz JL. Coronavirus pathogenesis. *Adv Virus Res* 2011; 81:85-164.

Wu, K., T. Liang, X. Duan, L. Xu, K. Zhang and R. Li. Anti-diabetic effects of puerarin, isolated from *Pueraria lobata* (Willd.), on streptozotocin-diabetogenic mice through promoting insulin expression and ameliorating metabolic function. *Food Chem. Toxicol*. 60: 341–347, 2013.

Yang D, Leibowitz JL. The structure and functions of coronavirus genomic 3' and 5' ends. *Virus Res* 2015; 206:120-33.
Zaki AM, Boheemen Sv, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367:1814-20.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W, Si H, Zhu Y, Li B, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*, 2020; 579(7798), 270-273

Zhu C, Wu Y, Jiang Z, Zheng C, Wang L, Yang X, et al. Dietary soy isoflavone attenuated growth performance and intestinal barrier functions in weaned piglets challenged with lipopolysaccharide. Int Immunopharmacol. (2015) 28:288–94.

**Tables**

**Table 1. Showing binding energy in Kcal/mol of puerarin with SARS-CoV-2**

| Compounds          | Docking Score (Kcal/mol) |
|--------------------|--------------------------|
| Puerarin with -OH  | -8.070                   |
| Puerarin with -O   | -4.658                   |
| Lopinavir          | -8.081                   |

**Table 2: The evaluation of the oral drug-likeness of the puerarin using Lipinski’s rule of five filters**

| compound | Molecular weight (Dalton) | Log P | Number of HBD | Number of HBA | Molar refractivity | XLogP |
|----------|---------------------------|-------|---------------|---------------|--------------------|-------|
| puerarin | 414.381                   | 1.77  | 6             | 9             | 104.59             | 0.01  |

HBD: Hydrogen bond donor; HBA: Hydrogen bond acceptor
### Table 3: ADMET properties of puerarin predicted from admetSAR

| ADMET                | Puerarin          |
|----------------------|-------------------|
| BBB                  | 0.0372427         |
| HIA                  | 54.397793         |
| Caco-2               | 6.03338           |
| Ames Toxicity        | Non-toxic         |
| Carcinogenicity      | Non-carcinogen    |
| MDCK                 | 3.99199           |
| Pgp inhibition       | Non               |
| CYP 2C19 inhibition  | Inhibitor         |
| CYP 2C9 inhibition   | Inhibitor         |
| CYP 2D6 inhibition   | Non               |
| CYP 2D6 substrate    | Non               |
| CYP 3A4 inhibition   | Inhibitor         |
| CYP 3A4 substrate    | Weakly            |
| Plasma Protein Binding | 54.383253        |
| Pure water solubility mg/L | 377.993 |
| Skin Permeability    | -4.6011           |

**Abbreviations:** ADMET: absorption, distribution, metabolism, and excretion-toxicity; BBB: Blood brain barrier; Caco-2: Caco-2 permeability; CYP, cytochrome; HIA: human intestinal absorption; MDCK: Madin Darby canine kidney; P-gp: permeability glycoprotein.

**Figures**
Figure 1

The three dimensional (3D) structure of SARS-CoV-2 main protease
Figure 2

3D structure of Puerarin (with –OH and –O) and Lopinavir

Figure 3

Binding pose and binding site of puerarin (OH) with SARS-CoV-2 main protease (Panel A), molecular interaction of puerarin with amino acid residues within the binding pocket of SARS-CoV-2 main protease (Panel B)
Figure 4

Binding pose and binding site of puerarin isomer (with −O) with SARS-CoV-2 main protease (Panel A), molecular interaction of puerarin isomer with amino acid residues within the binding pocket of SARS-CoV-2 main protease (Panel B)
Figure 5

Binding pose and binding site of lopinavir with SARS-CoV-2 main protease (Panel A), molecular interaction of lopinavir with amino acid residues within the binding pocket of SARS-CoV-2 main protease (Panel B)